Literature DB >> 20630764

N(epsilon)-Modified lysine containing inhibitors for SIRT1 and SIRT2.

Tero Huhtiniemi1, Tiina Suuronen, Maija Lahtela-Kakkonen, Tanja Bruijn, Sanna Jääskeläinen, Antti Poso, Antero Salminen, Jukka Leppänen, Elina Jarho.   

Abstract

Sirtuins catalyze the NAD(+) dependent deacetylation of N(epsilon)-acetyl lysine residues to nicotinamide, O'-acetyl-ADP-ribose (OAADPR) and N(epsilon)-deacetylated lysine. Here, an easy-to-synthesize Ac-Ala-Lys-Ala sequence has been used as a probe for the screening of novel N(epsilon)-modified lysine containing inhibitors against SIRT1 and SIRT2. N(epsilon)-Selenoacetyl and N(epsilon)-isothiovaleryl were the most potent moieties found in this study, comparable to the widely studied N(epsilon)-thioacetyl group. The N(epsilon)-3,3-dimethylacryl and N(epsilon)-isovaleryl moieties gave significant inhibition in comparison to the N(epsilon)-acetyl group present in the substrates. In addition, the studied N(epsilon)-alkanoyl, N(epsilon)-alpha,beta-unsaturated carbonyl and N(epsilon)-aroyl moieties showed that the acetyl binding pocket can accept rather large groups, but is sensitive to even small changes in electronic and steric properties of the N(epsilon)-modification. These results are applicable for further screening of N(epsilon)-acetyl analogues. Copyright (c) 2010. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20630764     DOI: 10.1016/j.bmc.2010.06.035

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  8 in total

1.  Peptides and Pseudopeptides as SIRT6 Deacetylation Inhibitors.

Authors:  Piia Kokkonen; Minna Rahnasto-Rilla; Päivi H Kiviranta; Tero Huhtiniemi; Tuomo Laitinen; Antti Poso; Elina Jarho; Maija Lahtela-Kakkonen
Journal:  ACS Med Chem Lett       Date:  2012-10-23       Impact factor: 4.345

2.  Azalysine analogues as probes for protein lysine deacetylation and demethylation.

Authors:  Blair C R Dancy; Shonoi A Ming; Romeo Papazyan; Christine A Jelinek; Ananya Majumdar; Yan Sun; Beverley M Dancy; William J Drury; Robert J Cotter; Sean D Taverna; Philip A Cole
Journal:  J Am Chem Soc       Date:  2012-03-12       Impact factor: 15.419

Review 3.  Sirtuin inhibitors as anticancer agents.

Authors:  Jing Hu; Hui Jing; Hening Lin
Journal:  Future Med Chem       Date:  2014-05       Impact factor: 3.808

4.  Versatile Peptide Macrocyclization with Diels-Alder Cycloadditions.

Authors:  Jeffrey E Montgomery; Justin A Donnelly; Sean W Fanning; Thomas E Speltz; Xianghang Shangguan; John S Coukos; Geoffrey L Greene; Raymond E Moellering
Journal:  J Am Chem Soc       Date:  2019-09-26       Impact factor: 15.419

Review 5.  Rejuvenating sirtuins: the rise of a new family of cancer drug targets.

Authors:  Santina Bruzzone; Marco Daniele Parenti; Alessia Grozio; Alberto Ballestrero; Inga Bauer; Alberto Del Rio; Alessio Nencioni
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

6.  Interpreting clinical assays for histone deacetylase inhibitors.

Authors:  Nadine Martinet; Philippe Bertrand
Journal:  Cancer Manag Res       Date:  2011-05-09       Impact factor: 3.989

Review 7.  Sirtuin functions and modulation: from chemistry to the clinic.

Authors:  Vincenzo Carafa; Dante Rotili; Mariantonietta Forgione; Francesca Cuomo; Enrica Serretiello; Gebremedhin Solomon Hailu; Elina Jarho; Maija Lahtela-Kakkonen; Antonello Mai; Lucia Altucci
Journal:  Clin Epigenetics       Date:  2016-05-25       Impact factor: 6.551

8.  Ligand-based virtual screening and inductive learning for identification of SIRT1 inhibitors in natural products.

Authors:  Yunan Sun; Hui Zhou; Hongmei Zhu; Siu-wai Leung
Journal:  Sci Rep       Date:  2016-01-25       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.